ChrysCapital to Acquire Linux Laboratories Stake
The Story: ChrysCapital is set to acquire a 20–25% stake in CNS-focused Linux Laboratories for around ₹600 crore, with Tata Capital Healthcare Fund II exiting its 15.35% holding.
The Take: The deal strengthens ChrysCapital’s position in India’s branded-generics market while giving Linux fresh capital to expand its neurology, psychiatry and dermatology portfolio.
Sanofi Partners with Tricog Health on AI Cardiac Diagnostics
The Story: Sanofi Healthcare India has signed a three-year LOI with Tricog Health to support its AI-powered cardiac diagnostic tools through mentorship, market access and potential investment.
The Take: The partnership could help Tricog scale its virtual cardiac diagnostics while strengthening Sanofi’s role in India’s health-tech and AI innovation ecosystem.
HRV Pharma to Invest ₹150 Crore in Peptides, Oncology APIs
The Story: HRV Pharma will invest around ₹150 crore to expand into synthetic peptides and high-potency oncology APIs, including ₹40–50 crore for dedicated peptide capacity and ₹100 crore in a strategic JV.
The Take: The investment strengthens HRV Pharma’s complex-molecule portfolio and access to regulated markets while supporting growth in supply-constrained pharmaceutical segments.
Novartis India to Acquire Minipress Trademarks for ₹1,250 Crore
The Story: Novartis India will acquire Pfizer’s Minipress and Minipres trademarks and related IP rights for around ₹1,250 crore, gaining the established Minipress XL (prazosin) brand used for hypertension and BPH.
The Take: The deal strengthens Novartis India’s cardiovascular portfolio with an established brand, while Pfizer exits Minipress XL following its decision to discontinue manufacturing the product.
